An experimental pancreatic cancer drug that’s been shown to double survival in patients with advanced stages of the disease is poised to revolutionize the way the cancer is treated, oncologists say.

The drug, called daraxonrasib, has already been fast-tracked for approval by the Food and Drug Administration. Last week, the agency said it would permit the drugmaker Revolution Medicines to give the drug to patients outside of clinical trials in an expanded access program, NBC news reported.

In April, Revolution Medicines released early findings from its Phase 3 clinical trial of the drug, which found that patients who got daraxonrasib in addition to chemotherapy saw double the survival time compared with patients who just got chemotherapy.

On Wednesday, results from an earlier phase of the clinical trial were published in the New England Journal of Medicine, showing that in patients whose cancer had spread to other parts of the body, daraxonrasib stopped tumors from getting worse for more than eight months and kept patients alive for up to nearly a year and a half.

Story Date: May 7, 2026